Kisspeptin
KISS1-derived kisspeptin peptides: Kisspeptin-54 (Metastin) and Kisspeptin-10 (Metastin 45-54, YNWNSFGLRF-NH2)
KISS1-derived neuropeptide that activates KISS1R upstream of GnRH neurons, rapidly increasing LH and FSH secretion in multiple small human studies in healthy volunteers and patients with reproductive disorders. Not FDA-approved; listed in FDA 503A Category 2 (September 2023) due to safety-data limitations. WADA prohibited since 2024 (PMID 24615662; PMID 26194072;;).
Last updated: 2026-03-10
Safety Summary
The clearest reproducible human tolerability issue is tachyphylaxis: twice-daily SC kisspeptin-54 leads to marked desensitization of LH/FSH response within 2 weeks in women with hypothalamic amenorrhea (PMID 19820030), mitigated by less frequent dosing (twice weekly maintained response over 8 weeks; PMID 26194072). Acute symptomatic safety reporting is limited in the filtered paper set. One 30-participant study in males reported no significant blood pressure change (PMID 30046307). Review literature notes kisspeptin has been 'well-tolerated' with no serious adverse effects across multiple trials (PMID 24615662, PMID 26194072). However, FDA has identified potential significant safety risks including immunogenicity and peptide impurity concerns for compounded kisspeptin-10, and notes limited human safety data overall. In chronic animal studies, prolonged kisspeptin-54 administration (50 nmol/day SC for 13 days) caused testicular weight reduction and seminiferous tubule degeneration in rats via HPG axis desensitization (PMID 35837314). Flushing and injection site reactions reported in clinical research context but not well-characterized in the filtered study set.
Known Side Effects
common
uncommon
uncommon
Who Should NOT Use This
Clinical inference: kisspeptin acutely stimulates sex hormone production. Chronic high-dose agonism may paradoxically suppress the HPG axis through desensitization (explored therapeutically for prostate cancer via TAK-448; PMID 35837314). Not explicitly listed as a contraindication in source papers.
Clinical inference: kisspeptin acts upstream of GnRH. Patients with GnRH receptor mutations would not respond to kisspeptin stimulation (PMID 24615662, PMID 16339030). Not explicitly listed as a contraindication in source papers.
Talk to Your Doctor
Before considering Kisspeptin, discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-18]
Evidence Assessment
Tier 3: Multiple controlled human studies demonstrate kisspeptin's potent stimulation of LH/FSH in healthy volunteers and patients with reproductive disorders (PMID 21470997, PMID 21632807, PMID 21976724, PMID 19820030, PMID 30046307). Phase 3 mechanistic studies completed (NCT03286517, NCT03771326, NCT03315325), but these are investigator-led physiological studies, not pivotal therapeutic approval trials. Kisspeptin-54 has been used as an IVF oocyte maturation trigger in clinical trials (PMID 24615662, PMID 26194072). However, kisspeptin is not FDA-approved, is listed in FDA 503A Category 2 with safety concerns, no pivotal Phase 3 efficacy/approval trials have been completed for a specific disease indication, and individual human studies have small sample sizes. Both evaluators agreed on Tier 3.
1Kisspeptin Resets the Hypothalamic GnRH Clock in MenPMID 21470997
Chan YM et al. - Journal of Clinical Endocrinology and Metabolism (2011) - Human interventional physiologic study - 13 healthy adult men
Single IV kisspeptin-10 bolus induced an immediate LH pulse in each subject (amplitude 5.0 +/- 1.0 vs 2.1 +/- 0.3 mIU/ml endogenous). Implied ~17 min sustained GnRH release. Reset the GnRH pulse generator by delaying next endogenous pulse.
Limitations: Small mechanistic study with acute dosing only.
2Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in MenPMID 21632807
George JT et al. - Journal of Clinical Endocrinology and Metabolism (2011) - Human interventional physiologic study - Healthy men; bolus cohort n=6, infusion cohorts n=4
Bolus dosing raised LH dose-dependently with maximal response at 1 ug/kg (LH: 4.1 +/- 0.8 to 12.4 +/- 2.0 IU/L at 30 min). 4 ug/kg/h infusion increased mean LH from 5.4 +/- 1.0 to 20.8 +/- 5.3 IU/L and testosterone from 16.6 +/- 2.4 to 24.0 +/- 2.5 nmol/L over 22.5 hours.
Limitations: Very small sample sizes and short-term endocrine endpoints.
3The Effects of Kisspeptin-10 on Reproductive Hormone Release Show Sexual Dimorphism in HumansPMID 21976724
Jayasena CN et al. - Journal of Clinical Endocrinology and Metabolism (2011) - Human interventional physiologic study - Healthy men and women; n=4-5 per group
Men responded to low-dose IV kisspeptin-10 with LH increases. Preovulatory women responded to IV bolus. Follicular-phase women showed no gonadotropin response to IV bolus up to 10 nmol/kg, SC bolus up to 3.2 nmol/kg, or IV infusion at 0.1 nmol/kg/min for 90 min.
Limitations: Very small exploratory groups. Menstrual-cycle-specific physiology limits generalization.
4Subcutaneous Injection of Kisspeptin-54 Acutely Stimulates Gonadotropin Secretion in Women With Hypothalamic Amenorrhea, but Chronic Administration Causes TachyphylaxisPMID 19820030
Jayasena CN et al. - Journal of Clinical Endocrinology and Metabolism (2009) - RCT - N=10 (5 kisspeptin, 5 saline)
First injection: potent LH increase (24.0 +/- 3.5 IU/L) and FSH increase (9.1 +/- 2.5 IU/L) in hypothalamic amenorrhea women. By day 14 of twice-daily dosing: LH response reduced to 2.5 +/- 2.2 IU/L (p<0.05), FSH to 0.5 +/- 0.5 IU/L (p<0.05). Subjects remained responsive to GnRH after kisspeptin treatment.
Limitations: Small sample size (n=5 per group). Single center. No long-term follow-up.
5Kisspeptin-10 Stimulates the Hypothalamic-Pituitary-Gonadal Axis in a Stage-Dependent Manner During Pubertal Transition in BoysNCT03286517PMID 30046307
Pita J et al. - Journal of Pediatric Endocrinology and Metabolism (2018) - Human interventional physiologic study (Phase 3 per ClinicalTrials.gov) - 25 boys across Tanner stages I-V plus 5 adult men
LH and testosterone increases after kisspeptin-10 were significant in Tanner stage V boys and adults but not in earlier pubertal stages. No significant blood-pressure change after infusion.
Limitations: Small stage-stratified cohort focused on endocrine responsiveness, not treatment outcomes.
6The Kisspeptin-GnRH Pathway in Human Reproductive Health and DiseasePMID 24615662
Skorupskaite K, George JT, Anderson RA - Human Reproduction Update (2014) - Systematic review - 390 manuscripts reviewed
Comprehensive review establishing kisspeptin as principal regulator of GnRH secretion in humans. Kisspeptin-54 half-life 27.6 +/- 1.1 min IV. Kisspeptin robustly stimulates LH in healthy men and women across multiple doses, routes, and isoforms. KNDy neurons in infundibular/arcuate nucleus coordinate pulsatile GnRH release.
Limitations: Review article synthesizing existing data. Some cited human studies had small sample sizes.
7Comprehensive Review on Kisspeptin and Its Role in Reproductive DisordersPMID 26194072
Not verified from paper file (Phase A attributed Skorupskaite; Phase B attributed Abbara) - Not verified (Phase A: BioMed Research International; Phase B: Endocrine) (2015) - Review - N/A
Kisspeptin administration to healthy humans stimulates gonadotropin release with no reported adverse effects. Kisspeptin-54 triggers oocyte maturation in IVF dose-dependently. Twice-weekly kisspeptin-54 sustained response over 8 weeks in hypothalamic amenorrhea. Kisspeptin may be novel target for fertility disorders, prostate cancer, reproductive diseases. Kisspeptin levels lower in miscarriage pregnancies.
Limitations: Review article. Author/journal attribution uncertain between evaluators; title verified from paper file.
8The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and ReproductionPMID 35837314
Hu KL et al. - Frontiers in Endocrinology (2022) - Review - N/A
Detailed kisspeptin signaling pathways (Gq/11-PLC-IP3/DAG-Ca2+/PKC-ERK). KNDy model for pulse generation. Roles in puberty, reproduction, clinical applications. TAK-448 analog showed stronger HPG axis suppression than GnRH analog in animal prostate cancer models. Kisspeptin-10 half-life ~4 min. Chronic kisspeptin-54 (50 nmol/day, 13 days) caused testicular degeneration in rats.
Limitations: Review. Some clinical application data from animal models only.
9Kisspeptin/Kisspeptin Receptor System in the OvaryPMID 29354093
Hu KL et al. - Frontiers in Endocrinology (2018) - Review - N/A
Intraovarian kisspeptin/KISS1R system: expressed in theca cells, granulosa cells, corpus luteum, oocytes. Kiss1r haploinsufficient mice display premature ovarian failure. Kisspeptin stimulates progesterone synthesis via ERK1/2 in luteal cells. Kisspeptin suppresses initial follicle recruitment via FSHR downregulation and AMH upregulation.
Limitations: Mostly animal model evidence. Limited human ovarian functional data.
10Minireview: Kisspeptin/Neurokinin B/Dynorphin (KNDy) Cells of the Arcuate Nucleus: A Central Node in the Control of Gonadotropin-Releasing Hormone SecretionPMID 20501670
Lehman MN et al. - Endocrinology (2010) - Review - N/A
KNDy subpopulation strongly conserved from rodents to humans. KNDy cells form reciprocally interconnected network with direct projections to GnRH cell bodies and terminals. Proposed as GnRH pulse generator component. Alterations in KNDy peptides may underlie PCOS neuroendocrine defects.
Limitations: Conceptual model. Functional confirmation in humans limited.
11Regulation of Gonadotropin-Releasing Hormone Secretion by Kisspeptin/Dynorphin/Neurokinin B Neurons in the Arcuate Nucleus of the MousePMID 19776272
Navarro VM et al. - Journal of Neuroscience (2009) - Animal study - Mouse model (knockout and wild-type)
Confirmed co-expression of Kiss1, Dyn, NKB, NK3, and KOR genes in arcuate nucleus neurons of female mice. All inhibited by estradiol. Proposed model: NKB and dynorphin act autosynaptically on kisspeptin neurons to synchronize pulsatile kisspeptin secretion.
Limitations: Mouse model. Electrophysiological confirmation not provided.
12Signaling of GPR54 and Its Role in Reproduction and PubertyPMID 16339030
Seminara SB et al. - Trends in Endocrinology and Metabolism (2005) - Review - N/A
Loss-of-function mutations in GPR54 (KISS1R) cause hypogonadotropic hypogonadism in humans. GPR54 expressed in GnRH neurons, placenta, pituitary. GPR54-null mice show small testes, absent follicular maturation, and low gonadotropins correctable by exogenous GnRH.
Limitations: Early review with limited clinical data.
13Postnatal Development of Kisspeptin Neurons in Mouse Hypothalamus; Sexual Dimorphism and Projections to Gonadotropin-Releasing Hormone NeuronsPMID 16959837
Clarkson J, Herbison AE - Endocrinology (2006) - Animal study - Mouse study; n=4-8 per age and sex group
Three kisspeptin neuron populations identified (AVPV/PeN, DMN, ARN). Marked 10-fold female-dominant sexual dimorphism in AVPV/PeN. Periventricular kisspeptin cell numbers increase from P25 through puberty. Kisspeptin fiber appositions to GnRH neurons appear around puberty.
Limitations: Mouse neuroanatomy study, not a human study.
14A Kisspeptin-10 Analog With Greater In Vivo Bioactivity Than Kisspeptin-10PMID 19934405
Curtis AE et al. (Imperial College London) - American Journal of Physiology - Endocrinology and Metabolism (2010) - In vitro + animal study - CHO-KISS1R cells + male C57BL/6 mice
Kisspeptin-10 C-terminal decapeptide YNWNSFGLRF-NH2 confirmed as minimal KISS1R-activating sequence. [dY]1KP-10 analog showed greater in vivo LH and testosterone stimulation than native KP-10 despite lower receptor binding affinity. Residues F6 and F10 critical for KISS1R binding.
Limitations: Mouse model for in vivo component. Translational relevance of analog uncertain. NOTE: Both Phase A and Phase B misidentified this paper.
15Kisspeptin Restores Placental mTOR Signaling and Glucose Metabolism Mediators in Hypothyroid Pregnant RatsPMID 41782211
Santos BR et al. - Journal of Cellular Physiology (2026) - Animal study - N=21-28 rats per group
Kisspeptin-10 (8 mcg/kg/day IP from GD8) restored placental p-mTOR/mTOR expression, normalized AKT signaling, upregulated IGF1/IGF1R axis. Did not reverse feto-placental growth restriction. First study evaluating IGF1/mTOR signaling in placenta of hypothyroid rats.
Limitations: Animal model (rat). KP-10 short half-life may limit sustained effects. No human data.
16Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in BoysNCT03286517
Not specified - ClinicalTrials.gov (2017) - Phase 3 (mechanistic/physiological, not therapeutic approval) - See PMID 30046307 (Pita et al.)
Completed. Results published as PMID 30046307.
Limitations: Mechanistic study, not a pivotal therapeutic trial.
17KP-10 and Insulin Secretion in MenNCT03771326
Not specified - ClinicalTrials.gov (2018) - Phase 3 (mechanistic/physiological, not therapeutic approval) - Not available in source data
Completed. Publication not identified in filtered set.
Limitations: Mechanistic study. Results not published in available source data.
18Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in MenNCT03315325
Not specified - ClinicalTrials.gov (2017) - Phase 3 (mechanistic/physiological, not therapeutic approval) - Not available in source data
Completed. Publication not identified in filtered set.
Limitations: Mechanistic study. Results not published in available source data.